SPRO Quote, Financials, Valuation and Earnings

Castle Biosciences has a net margin of -219.3% compared to Spero Therapeutics's net margin of 2.65%. Spero Therapeutics's return on equity of 4.36% beat Castle Biosciences's return on equity of 1.49%.

Spero Therapeutics has a consensus price target of $5.00, signalling upside risk potential of 433.33%. On the other hand Castle Biosciences has an analysts' consensus of $41.56 which suggests that it could grow by 49.91%. Given that Spero Therapeutics has higher upside potential than Castle Biosciences, analysts believe Spero Therapeutics is more attractive than Castle Biosciences.

Spero Therapeutics has a beta of 0.591, which suggesting that the stock is 40.892% less volatile than S&P 500. In comparison Castle Biosciences has a beta of 0.919, suggesting its less volatile than the S&P 500 by 8.114%.

Spero Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Castle Biosciences offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Spero Therapeutics pays -- of its earnings as a dividend. Castle Biosciences pays out -- of its earnings as a dividend.

Spero Therapeutics quarterly revenues are $7.8M, which are smaller than Castle Biosciences quarterly revenues of $85.8M. Spero Therapeutics's net income of -$17.1M is lower than Castle Biosciences's net income of $2.3M. Notably, Spero Therapeutics's price-to-earnings ratio is 11.72x while Castle Biosciences's PE ratio is 132.00x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Spero Therapeutics is 0.56x versus 2.50x for Castle Biosciences. Usually stocks with elevated PS ratios are considered overvalued.

CytomX Therapeutics has a net margin of -219.3% compared to Spero Therapeutics's net margin of 17.16%. Spero Therapeutics's return on equity of 4.36% beat CytomX Therapeutics's return on equity of --.

Spero Therapeutics has a consensus price target of $5.00, signalling upside risk potential of 433.33%. On the other hand CytomX Therapeutics has an analysts' consensus of -- which suggests that it could grow by 394.02%. Given that Spero Therapeutics has higher upside potential than CytomX Therapeutics, analysts believe Spero Therapeutics is more attractive than CytomX Therapeutics.

Spero Therapeutics has a beta of 0.591, which suggesting that the stock is 40.892% less volatile than S&P 500. In comparison CytomX Therapeutics has a beta of 1.069, suggesting its more volatile than the S&P 500 by 6.902%.

Spero Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CytomX Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Spero Therapeutics pays -- of its earnings as a dividend. CytomX Therapeutics pays out -- of its earnings as a dividend.

Spero Therapeutics quarterly revenues are $7.8M, which are smaller than CytomX Therapeutics quarterly revenues of $33.4M. Spero Therapeutics's net income of -$17.1M is lower than CytomX Therapeutics's net income of $5.7M. Notably, Spero Therapeutics's price-to-earnings ratio is 11.72x while CytomX Therapeutics's PE ratio is 6.29x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Spero Therapeutics is 0.56x versus 0.71x for CytomX Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Equillium has a net margin of -219.3% compared to Spero Therapeutics's net margin of -0.06%. Spero Therapeutics's return on equity of 4.36% beat Equillium's return on equity of -20.35%.

Spero Therapeutics has a consensus price target of $5.00, signalling upside risk potential of 433.33%. On the other hand Equillium has an analysts' consensus of -- which suggests that it could grow by 416.16%. Given that Spero Therapeutics has higher upside potential than Equillium, analysts believe Spero Therapeutics is more attractive than Equillium.

Spero Therapeutics has a beta of 0.591, which suggesting that the stock is 40.892% less volatile than S&P 500. In comparison Equillium has a beta of 1.782, suggesting its more volatile than the S&P 500 by 78.182%.

Spero Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Equillium offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Spero Therapeutics pays -- of its earnings as a dividend. Equillium pays out -- of its earnings as a dividend.

Spero Therapeutics quarterly revenues are $7.8M, which are smaller than Equillium quarterly revenues of $12.2M. Spero Therapeutics's net income of -$17.1M is lower than Equillium's net income of -$7K. Notably, Spero Therapeutics's price-to-earnings ratio is 11.72x while Equillium's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Spero Therapeutics is 0.56x versus 0.50x for Equillium. Usually stocks with elevated PS ratios are considered overvalued.

PTC Therapeutics has a net margin of -219.3% compared to Spero Therapeutics's net margin of -54.2%. Spero Therapeutics's return on equity of 4.36% beat PTC Therapeutics's return on equity of --.

Spero Therapeutics has a consensus price target of $5.00, signalling upside risk potential of 433.33%. On the other hand PTC Therapeutics has an analysts' consensus of -- which suggests that it could grow by 29.47%. Given that Spero Therapeutics has higher upside potential than PTC Therapeutics, analysts believe Spero Therapeutics is more attractive than PTC Therapeutics.

Spero Therapeutics has a beta of 0.591, which suggesting that the stock is 40.892% less volatile than S&P 500. In comparison PTC Therapeutics has a beta of 0.629, suggesting its less volatile than the S&P 500 by 37.101%.

Spero Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. PTC Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Spero Therapeutics pays -- of its earnings as a dividend. PTC Therapeutics pays out -- of its earnings as a dividend.

Spero Therapeutics quarterly revenues are $7.8M, which are smaller than PTC Therapeutics quarterly revenues of $196.8M. Spero Therapeutics's net income of -$17.1M is higher than PTC Therapeutics's net income of -$106.7M. Notably, Spero Therapeutics's price-to-earnings ratio is 11.72x while PTC Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Spero Therapeutics is 0.56x versus 3.85x for PTC Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.